Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KellBenx has licensed antibodies from AdnaGen which it will use to develop non-invasive prenatal diagnostics, AdnaGen's parent company, OncoVista Innovative Therapies said today.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders," OncoVista said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Independent advisors to the US Food and Drug Administration are to meet this week to discuss how they will make SARS-CoV-2 vaccine recommendations, the Washington Post reports.

The New York Times reports on how the US Food and Drug Administration has attempted to gird against pressure from the White House.

Researchers have identified a gene involved in how people determine when to urinate.

In Genome Research this week: assay for profiling chromatin accessibility, analysis of genetic variants among malaria-transmitting mosquitoes, and more.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.